Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | BACE1 | P56817 | 11/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29777802 | 0.97 | FOLH1 (0.55) | FOLH1PTPN1BACE1ERAP2ERAP1 | |
| SCHEMBL31042502 | 0.95 | BACE1 (0.48) | FOLH1PTPN1BACE1ERAP2ERAP1 | |
| SCHEMBL31750957 | 0.95 | BACE1 (0.48) | FOLH1PTPN1BACE1ERAP2ERAP1 | |
| SCHEMBL29760983 | 0.95 | BACE1 (0.48) | FOLH1PTPN1BACE1ERAP2ERAP1 | |
| SCHEMBL31672191 | 0.94 | FOLH1 (0.50) | FOLH1PTPN1BACE1BACE2CTSD | |
| SCHEMBL31672189 | 0.94 | FOLH1 (0.50) | FOLH1PTPN1BACE1BACE2CTSD | |
| SCHEMBL38658308 | 0.94 | PTPN1 (0.51) | FOLH1PTPN1BACE1BACE2CTSD | |
| SCHEMBL38659780 | 0.94 | PTPN1 (0.51) | FOLH1PTPN1BACE1BACE2CTSD | |
| SCHEMBL29777845 | 0.93 | FOLH1 (0.56) | FOLH1PTPN1BACE1ERAP2ERAP1 | |
| SCHEMBL30193392 | 0.92 | FOLH1 (0.60) | FOLH1ERAP2ERAP1LNPEPGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | SHENZHEN TURIER BIOTECH CO., LTD. | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | GCGR, GLP1R, GIPR | FOLH1 405/4885PTPN1 2709/4885BACE1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.